本草资本赞助的美中生物医药协会专家论坛 CABA Expert Forum在哈佛大学成功举办

2017年3月18日

CABA Expert Forum

美中生物医药协会专家论坛

2017年3月18日，礼拜六上午9-12点，美中生物医药协会（CABA)）和哈佛大学医学院中国学生学者联谊会（HMS-CSSA）将在哈佛大学医学院举办一个以肿瘤免疫治疗（Immuno-Oncology Therapy) 为主题的专家论坛和沙龙活动。

地址：哈佛大学丹娜法伯癌症研究所 DANA1620

Address: Dana-Farber Cancer Institute, DANA 1620, 450 Brookline Ave, Boston.

形式主要以圆桌讨论和解答问题为主，嘉宾讲座为辅，将会覆盖肿瘤免疫的几大方向：比如 small molecule、biologics and cell therapy、CART、checkpoint inhibitors、DC vaccine 等等。

活动目的在于提供给对此领域感兴趣的朋友一个和专家面对面交流和探讨的机会。活动完全免费。因位置有限，请速速报名。若有疑问，请联系truelancao@gmail.com。

HELLO VIP

部分嘉宾阵容

▼

Yangbing Zhao, MD, PhD

Dr. Yangbing Zhao is the Director of the T Cell Engineering Laboratory (TCEL), Center for Cellular Immunotherapies at the University of Pennsylvania, working closely with Dr. Carl June. He received an MD and PhD in Immunology from the Third Medical University in Chongqing, China. Prior to UPenn, Dr. Zhao has worked at The Weizmann Institute of Science, Duke University Medical Center, and NCI working with Dr. Steven Rosenberg. Dr. Zhao’s research work at NCI directly led to clinical trials of treating cancer patients with TCR or CAR engineered T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. Dr. Zhao’s Laboratory’s research and development work at UPenn has led to multiple clinical trials for the treatment of solid tumors with genetically engineered T cells against mesothelioma, pancreatic cancer, breast cancer and glioblastoma.

▼

Wenru Song, MD, Ph.D

Dr. Song is a physician-scientist-turned entrepreneur and is the co- founder of Kira Therapeutics, a new biotech startup based on cutting- edge immunological sciences. Dr. Song was most recently as the global VP and global clinical leader of Immuno-Oncology development at AstraZeneca Global Medicines Development where he initially led the Asia Pacific immune-oncology (IO) development and later led the global program for IO combinations and IO new indications. Previously, Dr. Song was the Head of Regional Oncology Development in Asia-Pacific at Millennium. Prior to joining Millennium, Dr. Song was a medical director/clinical lead at Pfizer Oncology where he led a number of cancer immunotherapy and antibody-drug conjugate (ADC) programs. Before joining the pharma-industry in 2008, he was an associate investigator at Baylor Institute of Immunology Research and an attending oncologist at Baylor Sammons Cancer Center in Dallas. He studied Medicine at Shandong University in China before coming to the US for his PhD study in Immunology. He then did a postdoctoral fellowship in cancer immunotherapy with Dr. Ron Crystal at Cornell University Medical Center, followed by medical residency training at Montefiore Medical Center/Albert Einstein College of Medicine, and clinical oncology fellowship at Stanford University where he also performed research on cancer immunotherapy with Drs. Ron Levy and Ed Engleman.

▼